FerriIridium: A Lysosome-Targeting Iridium(III) Prodrug for Iron(III)-Activated Chemotherapy in Gastric Cancer Cells.
We herein report the novel iron(III) activated lysosome-targeting iridium(III) prodrug FerriIridium , for gastric cancer theranostics. This complex contains a m -imino catechol group which can selectively bond to, and be oxidized by, free iron(III) inside the cell. Subsequent oxidative rearrangement releases iron(II) and hydrolyses the amine bond in acidic conditions and an aminobipyridyl iridium complex and 2-hydroxybenzoquinone are produced. This sequence of reactions has a threefold effect. First: iron (II) can catalyze the Fenton reaction transforming hydrogen peroxide into hydroxyl radicals. Second: benzoquinone compounds can interfere with the respiratory chain. Third: conversion from the prodrug to the amino-iridium complex leads to a remarkable increase in phosphorescence and toxicity. These properties, combined with the high iron(III) content and acidity of cancer cells, make FerriIridium a highly selective and efficient theranostic agent (IC 50 = 9.22 μM for AGS cells compared to >200 μM for LO2 cells). To the best of our knowledge, FerriIridium is the first metal-based compound that has been developed for chemotherapy using iron(III) to enhance both selectivity and potency.